Advisory Panel on COVID-19 Vaccines convenes meeting to conduct continuous benefit-risk analysis of authorised COVID-19 vaccines

Advisory Panel on COVID-19 Vaccines convenes meeting to conduct continuous benefit-risk analysis of authorised COVID-19 vaccines

     The Advisory Panel on COVID-19 Vaccines (Advisory Panel) convened a meeting today (September 30) to conduct continuous benefit-risk analysis of the authorised COVID-19 vaccines. The meeting was chaired by convenor Professor Wallace Lau Chak-sing.

     The Secretary for Food and Health (SFH) authorised two COVID-19 vaccines, namely the Comirnaty vaccine and the Sinovac vaccine, in accordance with the Prevention and Control of Disease (Use of Vaccines) Regulation (Cap. 599K) (the Regulation) on January 25 and February 18 respectively. To comply with the conditions of authorisation, the authorisation applicants are required to submit the latest clinical data on the vaccines, safety update reports and quality certification documents, etc. for continuous review and monitoring.

     At the meeting today, the Advisory Panel reviewed the continuous benefit-risk balance of the two authorised vaccines.  After reviewing all the latest available clinical and safety data related to the Comirnaty and Sinovac vaccines (including safety reports submitted by the authorisation applicants), the Advisory Panel considered that there was no other new significant safety signal identified, though continuous monitoring was required. The quality of the batches of Comirnaty and Sinovac vaccine imported has already passed the certification and appropriate testing for quality control. In summary, the Advisory Panel still considered that the benefits of the two vaccines outweighed the risks, and that there was no need to recommend changes regarding the use of the two vaccines.

     After reviewing the local COVID-19 epidemic situation and comparing the risks and benefits of receiving the second dose of Comirnaty vaccine by those aged 12 to 17, the Advisory Panel agreed with the updated recommendation made by the Scientific Committee on Vaccine Preventable Diseases and the Scientific Committee on Emerging and Zoonotic Diseases under the Centre for Health Protection of the Department of Health together with the Chief Executive’s expert advisory panel on September 15, which was that, after balancing the risks and benefits in the light of the local epidemic situation, those aged 12 to 17 are recommended to receive one dose of the Comirnaty vaccine. Furthermore, the Advisory Panel considered that, under the current usage conditions of the Comirnaty vaccine, the Government should continue to monitor the global and local epidemic situation and relevant clinical data on vaccines, and recommended the Government to consider undertaking a relevant scientific research study on the efficacy of providing the second dose of Comirnaty vaccine to those aged 12 to 17.

     The Advisory Panel will submit the relevant views to the SFH for consideration. The information concerned will be uploaded to the website of the Food and Health Bureau later on.

     “The Government will continue to ensure that the authorised vaccines satisfy the criteria of safety, efficacy and quality, and keep on disseminating the latest safety and scientific information on the relevant vaccines to the public and relevant stakeholders in a timely manner,” the spokesman said.

Ends/Thursday, September 30, 2021
Issued at HKT 21:22

NNNN

Note: This article have been indexed to our site. We do not claim ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
Supercross Results: San Diego thumbnail

Supercross Results: San Diego

2022 Monster Energy Supercross continues with the third stop in San Diego, Southern California, today. There is no sense of continuity in the 450SX class, as the results have differed so much from one week to the next, which means that it is impossible to predict what will take place at Petco Park. It is…
Read More
'Complotdocent' universiteit Groningen geschorst in afwachting van onderzoek thumbnail

‘Complotdocent’ universiteit Groningen geschorst in afwachting van onderzoek

Docent Tjeerd Andringa van de Rijksuniversiteit Groningen mag voorlopig geen college meer geven vanwege de complottheorieën die hij in zijn lessen zou hebben verkondigd. De universitair hoofddocent cognitieve wetenschappen is geschorst in afwachting van een onafhankelijk onderzoek dat de universiteit gaat instellen. Aanleiding voor de commotie rond Andringa is een artikel in het universiteitsblad Ukrant,…
Read More
Media arbitration law postponed...  The ruling and opposition parties "set up a special committee to discuss by the end of the year" thumbnail

Media arbitration law postponed… The ruling and opposition parties “set up a special committee to discuss by the end of the year”

여야가 언론중재법 개정안 본회의 상정을 연기하고, 국회에 특별위원회를 구성해 연말까지 논의하기로 했다.▲ 윤호중 더불어민주당 원내대표, 김기현 국민의힘 원내대표가 29일 서울 여의도 국회의장실에서 언론중재법 관련 회동을 마치고 취재진 질문에 답변하고 있다. [뉴시스]윤호중 민주당 원내대표와 김기현 국민의힘 원내대표는 박병석 국회의장 주재로 열린 29일 협상에서 이같이 최종 합의했다고 밝혔다.특위는 여야 동수 총 18명으로 구성된다. 언론중재법과 정보통신망이용촉진 및 정보보호법,…
Read More
'Pam', the "bisexual" and "transfeminist" Secretary of State for Equality who called a rival a "lame whore" thumbnail

'Pam', the “bisexual” and “transfeminist” Secretary of State for Equality who called a rival a “lame whore”

Ángela Rodríguez ha sido un puntal de la ley Trans y objetivo de las feministas, que ayer criticaron su nombramiento como "una ofensa a las mujeres"Ángela Rodríguez, 'Pam', a la derecha.TWITTER NATALIA PUGA Santiago Actualizado Viernes, 1 octubre 2021 - 22:35La dimisión de Noelia Vera, que el jueves dejó sus cargos públicos y orgánicos en…
Read More
Estimp (Republic) thumbnail

Estimp (Republic)

1.219 morți de COVID în primele șase zile din octombrie în România. Se poate ajunge la 10.000 lunar (Newsweek) Numai în primele șase zile din octombrie, media zilnică a deceselor cauzate de COVID în România a fost de 203. Ziua de miercuri, însă, a venit cu un număr de 331 de morți, ceea ce indică…
Read More
Index Of News
Total
0
Share